Leprosy Mailing List – November 13, 2020
Ref.: (LML) Clinical Trials need clinical outcomes
From: Gerson Penna, Brasilia, Brazil
Dear Pieter,
I would like to emphasize the comments of Prof. Diana Lockwood, on LML, November 8th 2020, regarding large randomized clinical trials.
The Uniform Multidrug Therapy for leprosy patients in Brazil (U-MDT/CT-BR), which was monitored for many years, presented indeed the robust results expected among multibacillary patients, from an open label, randomized and controlled clinical trial.
The authors are deep connoisseurs on Leprosy, including three senior epidemiologists and as far as we reviewed the literature we did not find, throughout the history of MDT, robust studies equal to the CT conducted by us and to the robust data of the Bangladesh study coordinated by Dr. Ruth Butlin.
In this sense and in the era of evidence-based medicine, alternative leprosy treatment proposals without proven clinical validity are not possible nor desirable.
Best regards,
Gerson Penna
Link CV Lattes
Link Grupo de Medicina Tropical UnB
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
--You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/fdd239b3-4e82-487f-9651-9894e546881fn%40googlegroups.com.
No comments:
Post a Comment